Trial Profile
An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine; Prednisone
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CALM
- Sponsors AbbVie
- 08 Jul 2019 Results evaluating the use of Adalimumab in a Tight Control (TC) approach with both biomarker-based and clinical symptom-directed strategy is cost-effective compared with Clinical Management (CM), are published in the Gut.
- 16 Oct 2018 According to an AbbVie media release, data will be presented at United European Gastroenterology (UEG) Week 2018.
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week